abstract:Mark Fishman is a noted researcher and clinician in cardiology and the current President of the Novartis Institutes for BioMedical Research (NIBR),http://www.novartis.
The company's move toward obscure diseases accelerated when Vasella lured Harvard cardiologist MarkFishman in 2003 to run research from a new lab in Cambridge, Mass.
Harvard Professor MarkFishman , who will leave his academic perch to run Novartis' Cambridge-based laboratory, believes that in the future most biological research will be possible both in drug companies and in academia, but some sliver of basic biology will still need to be done solely in academia.